Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Therapeutic strategies for COVID-19: progress and lessons learned
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Accelerating antiviral drug discovery: lessons from COVID-19
During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …
collaborative drug discovery efforts took place in academia and industry, culminating in …
Oral simnotrelvir for adult patients with mild-to-moderate Covid-19
B Cao, Y Wang, H Lu, C Huang, Y Yang… - … England Journal of …, 2024 - Mass Medical Soc
Background Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 …
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 …
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during …
coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during …
Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 (April 2020)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
Vaccines and therapeutics for immunocompromised patients with COVID-19
The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …
This diverse group is at increased risk for impaired vaccine responses, progression to …
COVID-19 drug discovery and treatment options
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …
Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
Objective To examine whether treatment with the antiviral agent molnupiravir during the first
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …
Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US veterans: target trial emulation studies with one-month and six-month …
Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …